ReviewJournal of translational medicine2026
The NLRP3 inflammasome as a dynamic context-dependent regulator: mechanisms, disease progression, and therapeutic implications.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The NLRP3 inflammasome is a central regulator of innate immunity and inflammation, but its functions extend beyond a simple pro-inflammatory role. Increasing evidence indicates that the biological consequences of NLRP3 activation are highly context-dependent, with protective or pathogenic effects determined by cellular composition, tissue microenvironment, and disease stage. In this review, we examine NLRP3 biology across three interconnected dimensions: cellular context, including immune and non-immune compartments; microenvironmental context, including infectious versus sterile inflammation and tissue repair versus tissue damage; and disease context, including stage- and time-dependent functional shifts. We further discuss three major determinants of NLRP3 output: cytokine bias between IL-1β and IL-18, cell-fate decisions between pyroptosis and survival, and epigenetic programming of inflammasome-responsive states. Using representative disease settings such as cancer, inflammatory bowel disease, and autoimmune disorders, we illustrate how similar NLRP3 activation can lead to divergent biological outcomes. We also discuss the therapeutic implications of this plasticity, arguing that effective intervention will require context-selective rather than universal inhibition. A more precise understanding of NLRP3 context dependence may support rational trial design, biomarker development, future patient-stratification frameworks, and more biologically informed therapeutic strategies in NLRP3-related diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.